Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02096861 · ClinicalTrials.gov registry record · Phase 3
Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease
A Phase 3 study of Crohn's Disease, sponsored by Celltrion.
- Completed
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
- 1
- Study location
NCT02096861 is a Phase 3 study of Crohn's Disease that has completed, run by Celltrion. The registered enrollment target is 220 participants, below the 2,392-participant average among 105 other Crohn's Disease trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02096861, a Phase 3 study of Crohn's Disease, has completed, sponsored by Celltrion.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to assess noninferiority in efficacy and to assess overall safety of CT P13 compared to Remicade in patients with active Crohn's disease up to Week 54.
Conditions Studied
Interventions
- BIOLOGICAL CT-P13
- BIOLOGICAL Remicade
Study Locations (1)
Tennessee
- Nashville Medical Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2014-09-19 |
| Est. Completion | 2017-02-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02096861
The ClinicalTrials.gov registry entry for NCT02096861 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,392-participant average among 105 other Crohn's Disease trials with a reported enrollment target (91% lower). The listed sponsor is Celltrion, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which CT-P13 is the first listed.
NCT02096861 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT02096861 about?
NCT02096861 is a clinical study titled "Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease". This study is to assess noninferiority in efficacy and to assess overall safety of CT P13 compared to Remicade in patients with active Crohn's disease up to Week 54.
What is the current status of trial NCT02096861?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2014-09-19. Estimated completion is 2017-02-15.
What conditions does trial NCT02096861 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT02096861?
The interventions under investigation include: CT-P13 (BIOLOGICAL), Remicade (BIOLOGICAL).
Who is sponsoring clinical trial NCT02096861?
This trial is sponsored by Celltrion, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02096861 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
RECRUITING · Phase 3
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RECRUITING · Phase 3
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RECRUITING · Phase 3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.